Prima BioMed to Host Investor Days in Australia

Prima BioMed to Host Investor Days in Australia 
SYDNEY, AUSTRALIA -- (Marketwire) -- 01/23/13 --  Prima BioMed Ltd
(ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the
Company") is pleased to announce upcoming investor days at several
major Australian cities in February.  
Prima CEO, Matthew Lehman will host the sessions, to be held in
Sydney, Melbourne, Brisbane and Perth, in the week commencing 4
February 2013. 
Mr. Lehman will provide an update on the Company's business and
attendees will have an opportunity for Q&A.  
Details of dates and venues are provided below. 
Perth
 Monday, 4th
February
 Parmelia Hilton Hotel, 14 Mill St, Perth
 10.00am - 11.30am
local time 
Melbourne
 Tuesday, 5th February
 Westin Melbourne Hotel,
205 Collins St, Melbourne
 10.30am - 12.00noon local time  
Brisbane 
Wednesday, 6th February
 Hilton Brisbane Hotel, 190 Elizabeth St,
Brisbane 
 10.00am - 11.30am local time 
Sydney
 Thursday, 7th
February
 Radisson Blu Hotel, 27 O'Connell St, Sydney
 10.30am -
12.00noon local time 
Shareholders and other interested parties are kindly requested to
help assure appropriate accommodations by sending an RSVP by email to
enquiries@primabiomed.com.au and identify the city of attendance by
Friday 1st February.  
About Prima BioMed
 Prima BioMed is a globally active biotechnology
company. As a leader in personalized bio-therapeutic products for
cancer, Prima is dedicated to leveraging its current technology and
expertise to develop innovative treatment options for patients and
maximize value to shareholders. Prima's lead product is CVac(TM), an
autologous dendritic cell product currently in clinical trials for
ovarian cancer patients who are in remission. 
For further information please contact: 
USA Investor/Media:
Ms. Jessica Brown
Prima BioMed Ltd. 
+1 (919) 710-9061
jessica.brown@primabiomed.com.au 
Australia Investor/Media:
Mr. James Moses
Mandate Corporate 
+61 (0) 420 991 574
james@mandatecorporate.com.au  
Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
amuehlhaus@edicto.de